Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? by Orsolini, Giovanni et al.
LETTER Open Access
Is the exposure to bisphosphonates or
osteoporosis the predictor of spinal
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Idolazzi Luca, Gatti Davide and Viapiana Ombretta
We read with great interest the paper by Deminger et al.
[1] reporting determinants of radiographic progression
in ankylosing spondylitis (AS). Intriguingly, the authors
found bisphosphonate exposure during follow up to be a
predictor of spinal radiographic progression in women.
Correctly, the authors declared that their results are
based on few observations and should be interpreted
with caution. Indeed, it is known that the prevalence of
osteoporosis, the main indication for bisphosphonate
use, is high in AS patients [2] and associated with radio-
graphic progression of the disease [3].
Unfortunately, the study presented lacks data on
osteoporosis prevalence, bone mineral density, vertebral
fractures, or bone turnover markers in the patients en-
rolled. Considering the pathophysiology of the disease,
there’s rationale for a positive rather than negative effect
of bisphosphonates. First, they lower bone resorption,
which is known to be elevated at least in the early stages
of AS. Second, suppression of bone resorption by
bisphosphonates would lead, through the coupling of
osteoclast and osteoblast activity, to later inhibition also
of bone formation and to an increase in serum sclerostin
[4], an inhibitor of the anabolic bone Wnt pathway and
which has been described to be low in AS and negatively
correlated to the development of syndesmophytes [5].
Although interesting, the conclusion of the authors
might send an alarming message on bisphosphonate use
in AS that could worsen an already low treatment rate
of osteoporosis and vertebral fracture in those patients,
complicating their disability. In our opinion the hypoth-
esis that the association observed was due to more se-
vere bone loss in those patients who show radiographic
progression and that leads to the use of bisphosphonates
should be considered and further investigated.
Abbreviation
AS: Ankylosing spondylitis
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